EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word (s): Quarterly / Interim Statement/Quarter Results SCHOTT Pharma records good start into fiscal year and confirms full year outlook 13.02.2025 / ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), ...

Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...

We recently compiled a list of the Top 10 Must-See AI News Updates for Investors. In this article, we are going to take a ...

Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies. You can obtain detailed information about the use of cookies ...

CNW/ - Canada Pension Plan Investment Board (CPP Investments) ended its third quarter on December 31, 2024, with net assets ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Pablo Legorreta, CEO, highlighted strong 2024 performance, with Portfolio Receipts reaching $2.8 billion, at the high end of guidance and representing 13% growth in Royalty Receipts. He noted this ...

Arabian Business unveils its 2025 list of 100 Most Inspiring Women, showcasing the female leaders transforming the Middle ...

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...

Enter Telegraph 25, the list of our favourite investment funds. It is a mixture of funds that we believe will grow your money ...

Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion) as it ...